Full Text - Purpose: This study aimed to validate the newly proposed American Joint Committee on Cancer (AJCC) pathological prognostic staging system for young breast cancer patients (aged ≤40 years).Results: We included 12811 women in this study. Overall, 52.8% of patients in the 7th AJCC stages were restaged to the 8th AJCC pathological staging system, including 10.7% upstaged and 42.1% downstaged. The receiver operating characteristics analysis showed that the new staging system had a better role in predicting breast cancer-specific survival (BCSS) compared with 7th edition staging (P<0.001). The results of the multivariate prognostic analysis showed that the hazard ratio of BCSS increased with the 8th AJCC stages, while the 7th anatomic stages had no significant difference in BCSS.Conclusions: The novel pathological staging system could provide more accurate prognostic stratification for young women with breast cancer because of the high proportion of stage migration.Patients and Methods:

PubMed journal article: Prognostic significance of the lymph node ratio in stage IV colorectal cancer patients who have undergone curative resection. Download Prime PubMed App to iPhone, iPad, or Android

Fingerprint Dive into the research topics of Clinicopathological Factors Associated with Recurrence and Prognosis after R0 Resection for Stage IV Colorectal Cancer with Peritoneal Metastasis. Together they form a unique fingerprint. ...

Whether to perform primary tumor resection in patients with asymptomatic Stage IV colorectal cancer remains controversial; however, the more aggressively we perform radical resection and metastasectomy to selected patients, the more survival benefits the patients obtain.

title: Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea, doi: 10.1097/MPA.0000000000000586, category: Article

BACKGROUND: Identification of high-risk stage II colorectal cancer (CRC) patients, potential candidates for adjuvant chemotherapy, is challenging. Current clinical guidelines rely mainly on histopathological markers with relatively weak prognostic value. This motivates further search for prognostic markers.. METHODS: This explorative study aimed to identify potential candidate gene mutations to facilitate differentiation between subgroups of patients with CRC stage II. Panel-based massive parallel sequencing was used to genetically characterize tumor tissues from 85 patients radically operated for CRC stage II, of which 12 developed recurrent cancer during follow-up. Genetic data was compared between patients with or without cancer recurrence, between tumors located in colon and in rectum, and for association with tumor differentiation grade.. RESULTS: Genetic variation in ATM, C11ORF65 was associated with recurrence-free survival. Previous reports regarding the association between BRAF mutation ...

After integrating MPV and PDW/PCT into the multivariable Cox model, we developed a new prognostic model and a novel staging system. The OS of patients belonging to different stages were significantly different, either limited to specific types of BTC or the entire BTC cohort. Meanwhile, the AJCC 7th TNM staging system presented modest prognostic power in patients with ECC (Fig. 3H), and has been shown to have poor prognostic performance in several subsets of patients with BTC [25]. The C-index of our novel prognostic model was 0.703 in the training cohort and 0.728 in the validation cohort. Compared to the AJCC TNM stage, with a C-index of 0.561 and 0.618, our prognostic model has superior discrimination to the AJCC TNM stage. DCA also implied increased clinical benefits with the utility of our new staging system. Based on these results, we can conclude that our new prognostic model outperformed the AJCC TNM staging system in many aspects. An obvious advantage of our new prognostic model is the ...

Neoadjuvant chemoradiation decreases the risk of local recurrence in locally advanced rectal cancer and is therefore indicated by guidelines in patients with positive nodal status (cN+) or cT3/4 tumors. On the other hand is neoadjuvant chemoradiation associated with relevant side effects and long term complications such as loss of sexual activity and fecal incontinence. However, accuracy of routine pretherapeutic lymph node staging (cN) in rectal cancer with MR imaging is still limited which can lead to overstaging and overtreatment. Few studies have shown a distinct improvement of the diagnostic accuracy of nodal staging (cN) by applying morphologic criteria (altered border contour and inhomogeneous signal intensity) instead of the established size criterion. The aim of the study was to determine and compare accuracy, sensitivity and specificity of the size criterion and morphological criteria in nodal staging. LN in preoperative MRI of 60 patients with rectal cancer and primary surgery that ...

INTRODUCTION] An accurate preoperative rectal cancer staging is crucial to the correct management of the disease. Despite great controversy around this issue, pelvic magnetic resonance (RM) is said to be the imagiologic standard modality. This work aimed to evaluate magnetic resonance accuracy in preoperative rectal cancer staging comparing with the anatomopathological results. METHODS We calculated sensibility, specificity, positive (VP positive) and negative (VP negative) predictive values for each T and N. We evaluated the concordance between both methods of staging using the Cohen weighted K (Kw), and through ROC curves, we evaluated magnetic resonance accuracy in rectal cancer staging. RESULTS 41 patients met the inclusion criteria. We achieved an efficacy of 43.9% for T and 61% for N staging. The respective sensibility, specificity, positive and negative predictive values are 33.3%, 94.7%, 33.3% and 94.7% for T1; 62.5%, 32%, 37.0% and 57.1% for T2; 31.8%, 79%, 63.6% and 50% for T3 and ...

OUTLINE: Patients receive vaccination comprising HER-2-neu and carcinoembryonic antigen synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51 on days 1, 8, and 15. On day 22, patients undergo removal of the lymph node into which the vaccination site drains to determine whether the immune system is responding to the vaccine.. PROJECTED ACCRUAL: A maximum of 15 patients will be accrued for this study. ...

Breast cancer stage 3 describes the breast cancer has extend to the underarm lymph nodes and muscles but not spread to more distant sites in the body. This stage is divided into three groups, breast cancer stage 3A, 3B and 3C.

The purpose of this study is to determine the safety of SU011248 and the highest dose of this drug that can be given safely in combination with the chemotherapy drugs irinotecan and cetuximab. Laboratory studies have shown that SU011248 may block the growth of blood vessels in tumors, which may prevent tumors from growing any further. Other studies have demonstrated the possibility that SU011248 may enhance the anti-tumor activity of other chemotherapy drugs such as irinotecan and cetuximab ...

Surgery and radiotherapy may not be suitable for most breast cancer stage 4 patients. Here are the suggested treatment options for patients with breast cancer stage 4.

Stage III breast cancer requires local therapy such as surgery and/or radiation and systemic therapy such as chemotherapy, hormonal or biological therapy.

Colorectal cancer (CRC) is the third most frequently diagnosed cancer, and second leading cause of cancer-related deaths in the United States (1). Current prognosis for patients with CRC predominantly relies on pathologic Unio Internationale Contra Cancrum/American Joint Committee on Cancer (UICC/AJCC) tumor-node-metastasis (TNM) staging classification (2). Although TNM staging successfully stratifies high-risk patients, there is significant variability in the rate of disease progression within each stage. Particular concern exists for early-stage disease (stage I and II) where patients can progress more rapidly than expected. It is well known that approximately 30% of patients with stage II CRC die of recurrent and metastatic disease. Identification of patients at risk of recurrence/progression could inform clinicians on adjuvant chemotherapeutic treatment decisions. Biomarkers can assist in identifying those patients who require more aggressive intervention or patients at risk of relapse after ...

Individualized approaches to prognosis are crucial to effective management of cancer patients. We developed a methodology to assign individualized 5-year disease-specific death probabilities to 1,222 patients with melanoma and to 1,225 patients with breast cancer. For each cancer, three risk subgroups were identified by stratifying patients according to initial stage, and prediction probabilities were generated based on the factors most closely related to 5-year disease-specific death. Separate subgroup probabilities were merged to form a single composite index, and its predictive efficacy was assessed by several measures, including the area (AUC) under its receiver operating characteristic (ROC) curve. The patient-centered methodology achieved an AUC of 0.867 in the prediction of 5-year disease-specific death, compared with 0.787 using the AJCC staging classification alone. When applied to breast cancer patients, it achieved an AUC of 0.907, compared with 0.802 using the AJCC staging classification

We compared the prognostic value of the American Joint Committee on Cancer (AJCC) TNM nodal staging system with that of lymph node (LN) density in patients with

TY - JOUR. T1 - Microrna-9-5p-CDX2 axis. T2 - A useful prognostic biomarker for patients with stage II/III colorectal cancer. AU - Nishiuchi, Aya. AU - Hisamori, Shigeo. AU - Sakaguchi, Masazumi. AU - Fukuyama, Keita. AU - Hoshino, Nobuaki. AU - Itatani, Yoshiro. AU - Honma, Shusaku. AU - Maekawa, Hisatsugu. AU - Nishigori, Tatsuto. AU - Tsunoda, Shigeru. AU - Obama, Kazutaka. AU - Miyoshi, Hiroyuki. AU - Shimono, Yohei. AU - Mark Taketo, M.. AU - Sakai, Yoshiharu. PY - 2019/12. Y1 - 2019/12. N2 - A lack of caudal-type homeobox transcription factor 2 (CDX2) protein expression has been proposed as a prognostic biomarker for colorectal cancer (CRC). However, the relationship between CDX2 levels and the survival of patients with stage II/III CRC along with the relationship between microRNAs (miRs) and CDX2 expression are unclear. Tissue samples were collected from patients with stage II/III CRC surgically treated at Kyoto University Hospital. CDX2 expression was semi-quantitatively evaluated by ...

In a recent article in the journal Brachytherapy, The American Brachytherapy Societys Ophthalmic Oncology Task Force adopted the AJCC staging rules for melanoma of the uvea.. [The] AJCC uveal melanoma T-staging system has been shown to predict metastasis in more than 7000 cases...the use of tumor, node, and metastasis staging brings ophthalmic oncology into the mainstream of general oncology. Clearly, universal staging promotes multicenter cooperation and data analysis.. Cancer staging rules published in the AJCC Cancer Staging Manual, 7th Edition were made effective for all cancer cases diagnosed on or after January 1, 2010. Paul T. Finger, MD, New York University, chaired the AJCC Ophthalmic Expert Panel for the 7th Edition, and will serve as Chair for the 8th Edition. Sarah Coupland, MBBS, PhD, Royal Liverpool University, will serve as Vice Chair. The 8th Edition is scheduled for release in Fall 2016.. ...

The most common staging system is the TNM (for tumors/nodes/metastases) system, from the American Joint Committee on Cancer (AJCC). The TNM system assigns a number based on three categories. T denotes the degree of invasion of the intestinal wall, N the degree of lymphatic node involvement, and M the degree of metastasis. Possibly, the The overall AJCC stage is a shorter format of the TNM stage, and is usually quoted as a number I, II, III, IV derived from the TNM value grouped by prognosis; a higher number indicates a more advanced cancer and likely a worse outcome. Following is the eighth edition from 2017: ...

Background Staging investigations for metastatic disease are not recommended for asymptomatic patients with early breast cancer. However, it is relatively common practice to perform staging in patients who are heavily node positive (4 or more nodes involved). This study explored the benefit of routine investigations in this patient group.. Methodology All patients operated in Castle Hill Hospital, Hull, UK between January 2005 and December 2011 for early breast cancer and found to have 4 or more nodes involved on pathological assessment were identified. Staging investigations, consisting of CT chest, abdomen and pelvis and isotope bone scan, were reviewed. The need for additional investigations was recorded.. Results A total of 231 patients were identified. 59 patients were excluded as no staging investigations were performed. In the remaining 172 patients staging investigations were positive in 12% (21/172). An additional 17% (29/172) required further investigations for equivocal scans and were ...

A recent study published in the journal Cancer last month compared the survival of 8,988 kidney cancer patients from the American National Cancer Data Base to assess the impact of cancer spread to the lymph nodes in patients with stage III renal cell carcinoma (RCC).. The researchers found that the 5-year survival rate of patients with cancer spread to their lymph nodes (lymph node-positive stage III disease) was 23% and was more like that of patients with stage IV disease (16%) than patients with lymph node-negative stage III disease (62%).. This study may help to explain the lack of survival benefit with adjuvant therapy in patients with stage III RCC and positive lymph nodes, particularly adjuvant therapy with TKIs (e.g. the ASSURE trial). Also, it may help to explain outcomes in stage III patients who have surgical removal of their positive lymph nodes and survival similar to that of patients with stage IV disease.. In conclusion, the results from this study support the finding that patients ...

OUTLINE: Patients are randomized to 1 of 3 arms.. Arm I: Patients receive binimetinib orally (PO) twice daily (BID) for a lead-in period of 15 days in the absence of disease progression or unacceptable toxicity. Patients then receive binimetinib orally (PO) twice daily (BID) on days 1-28 and avelumab intravenously (IV) over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Arm II: Patients receive anti-OX40 antibody PF-04518600 IV over 60 minutes for a for lead-in period of 15 days in the absence of disease progression or unacceptable toxicity. Patients then receive anti-OX40 antibody PF-04518600 IV over 60 minutes and avelumab IV over 60 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.. Arm III: Patients receive utomilumab IV over 60 minutes for a lead-in period of 15 days in the absence of disease progression or unacceptable toxicity. Patients then receive ...

Staging is how physicians determine the extent of your cancer, where it is located, and whether it has metastasized to nearby organs or tissue or to other parts of your body.. The TNM staging system, developed by the American Joint Committee on Cancer (AJCC), is typically used to stage head and neck cancers. This system classifies the cancer by tumor (T), node (N) and metastasis (M). The T category describes the size and location of the primary tumor. The N category describes lymph node involvement, indicating whether the lymph nodes show evidence of cancer cells. The location of these lymph nodes is important because it shows how far the disease has spread. The pathologic N category (sometimes denoted as pN) describes how many lymph nodes are involved and the amount of tumor cells found in the nodes. The M category describes distant metastasis (spread of cancer to another part of the body), if any. Staging for the M category is mainly clinical; however, a new M subcategory may be given based on ...

Endoscopic ultrasonography (EUS) is the single best modality for staging esophageal cancer with respect to depth of tumor infiltration and extent of lymph node involvement using the TNM classification system. The accuracy of EUS for staging patients with esophageal carcinoma who subsequently underwent surgery for confirmation ranged from 59% to 92% (with a mean of 84% in 1154 patients); the accuracy for N staging ranged from 50% to 90% (with a mean of 77% in 1035 patients). Endosonography is superior to CT in the T and N staging of disease. However, EUS is not a sensitive tool for diagnosing tumor involvement of the trachea and bronchial tree, because these structures contain air. Bronchoscopy should be used for the staging of proximal esophageal cancers. If esophageal cancers obstruct the lumen and the EUS endoscope cannot be advanced through, tumor staging is incomplete. EUS employs the technology of endoscopy and internally placed high-frequency ultrasound waves to visualize the ...

In addition, the prognosis of our patients with EUS non-traversable EC may have been further worsened by the limited EUS assessment of EC stage. EUS is a standard locoregional staging modality for EC, demonstrating high T (80% to 90%) and N staging accuracy (70% to 80%) that is clearly superior to CT and magnetic resonance imaging [3,4]. However, the accuracy of EUS decreases significantly when an echoendoscope cannot pass through EC. Staging accuracy of EUS is reportedly 46% in EUS non-traversable EC (vs. 92% in EUS traversable EC) and correct preoperative T stage was obtained using EUS only in 30.8% of patients with high-grade EC stenosis (vs. 81% of patients with less severe EC stenosis) [6,22]. A previous study reported that 9.9% of patients with distant metastatic nodes were found on EUS after EC stenosis dilation [23]. Another study on the effects of EUS after dilation of EC stenosis reported that EUS detected additional cases of advanced diseases in 19% of patients, including celiac node ...

1 of 2 NCCN QUICK GUIDE tm Breast Cancer - Metastatic (STAGE IV), Version 1.2017 This NCCNQUICK GUIDE tm sheet summarizes key points from the complete NCCN Guidelines for Patients ® : Breast Cancer - Metastatic (STAGE IV) . These guidelines explain which tests and treatments are recommended by experts in cancer. To view and download the guidelines, visit NC C N.or g /patients or, to order printed copies, visit Amazon.com. What is metastatic breast cancer? It is cancer that has spread outside the breast to a distant site. Distant sites include bones, lungs, liver, and the brain. Stage IV breast cancer is metastatic cancer that was found at diagnosis. 12 What health care is needed before treatment? ■ A report of your health history and an exam of your body 14 ■ Blood tests to check for health problems 15 ■ Pictures of the insides of your chest with a CT scan 16 ■ Pictures of the insides of your belly area and maybe pelvis with CT or MRI scans 16 ■ Pictures of your spine, brain, or both ...

As the worlds oldest and largest private cancer center, Memorial Sloan-Kettering Cancer Center (MSKCC) is committed to exceptional patient care, leading-edge research, and superb educational programs. The close collaboration between its physicians and scientists is one of the Centers core strengths. At Sloan-Kettering Institute, state-of-the-art research flourishes side-by-side with clinical investigation and treatment at Memorial Hospital, the nations oldest cancer hospital. An essential component of MSKCCs mission is education-training future clinicians and scientists and providing unique programs in the study of biomedical sciences to advance the standard of cancer care worldwide.The Center has more than 9,000 employees and last year had more than 21,000 inpatient admissions. The Center accommodated more than 430,000 outpatient visits at its Manhattan and regional sites combined.Robert E. Wittes, MD (second picture on the cover), is Physician-in-Chief of Memorial Hospital. A graduate of ...

PATIENTS AND METHODS: Ten potential prognostic factors were investigated in 94 patients receiving radiotherapy for recurrent rectal cancer: age (,or=68 vs. ,or=69 years), gender, Eastern Cooperative Oncology Group performance status (0-1 vs. 2-3), American Joint Committee on Cancer (AJCC) stage (,or=II vs. III vs. IV), grading (G1-2 vs. G3), surgery, administration of chemotherapy, radiation dose (equivalent dose in 2-Gy fractions: ,or=50 vs. ,50 Gy), and hemoglobin levels before (,12 vs. ,or=12 g/dL) and during (majority of levels: ,12 vs. ,or=12 g/dL) radiotherapy ...

This study is investigating the efficacy and safety of cediranib [AZD2171; Recentin] in patients with breast cancer stage IV. The primary endpoints are outcomes

Owner of Rave Home Staging, located in Jacksonville, FL, Melissa Marro is one of the best known stagers in the industry. Formerly the Chairman of the Board for the Real Estate Staging Association, she keynotes at International staging conventions annually. Having grown not one, but two large home staging companies, one in FL and one in SC, in the last decade, her no-nonsense marketing techniques can help transform any staging business into a top producing local brand. Marro is also one of the only staging training providers to actually successfully build a staging company. With over 500 residential homes staged in 2019, and gross sales in excess of $1.25 M annually, Rave is one of the largest staging companies in North America.. ...

PATIENTS AND METHODS: Ten potential prognostic factors were investigated in 94 patients receiving radiotherapy for recurrent rectal cancer: age (,or=68 vs. ,or=69 years), gender, Eastern Cooperative Oncology Group performance status (0-1 vs. 2-3), American Joint Committee on Cancer (AJCC) stage (,or=II vs. III vs. IV), grading (G1-2 vs. G3), surgery, administration of chemotherapy, radiation dose (equivalent dose in 2-Gy fractions: ,or=50 vs. ,50 Gy), and hemoglobin levels before (,12 vs. ,or=12 g/dL) and during (majority of levels: ,12 vs. ,or=12 g/dL) radiotherapy ...

Breast cancer stages help determine your treatment. In general, the earlier the stage of breast cancer, the better the prognosis will be.

Despite undergoing complete surgical removal of the cancer, 25-40% of patients with Stage II colon carcinoma experience recurrence of their cancer.

Although the most important prognostic and predictive marker in colorectal cancer is tumor cells in lymph nodes, ∼30% of patients who are node-negative die from occult metastases. Molecular staging employing specific markers and sensitive detection technologies has emerged as a powerful platform to assess prognosis in node-negative colon cancer. Integrating molecular staging into algorithms that individualize patient management will require validation and the definition of relationships between occult tumor cells, prognosis, and responses to chemotherapy. J. Surg. Oncol. 2012; 105:468-474. © 2012 Wiley Periodicals, Inc. ...

of response to neoadjuvant therapy in stage IIIA NSCLC patients in relation to T factor and N factor; evaluation of TNM classification before and after use of neoadjuvant therapy in stage IIIA NSCLC patients; determination of degree of tumor regression with pathohistologic analysis of resection specimen of NSCLC obtained from patients after application of neoadjuvant therapy, as a prognostic factor for disease-free period and overall survival rate; and determination of degree of tumor regression in malignant lymph nodes after application of neoadjuvant therapy in stage IIIA NSCLC patients, as a prognostic factor for disease-free period and overall survival rate. Results have shown that neoadjuvant therapy according to RECIST criteria leads to significant reduction of tumor size, T factors, as well as significant downstaging of nodal status, N factor, in treatment of stage IIIA NSCLC patients. Furthermore, neoadjuvant therapy according to RECIST criteria leads to significant reduction of clinical ...

TY - JOUR. T1 - Predicting the prognosis of lung cancer. T2 - The evolution of tumor, node and metastasis in the molecular age-challenges and opportunities. AU - Rami-Porta, Ramón. AU - Asamura, Hisao. AU - Goldstraw, Peter. PY - 2015. Y1 - 2015. N2 - The tumor, node and metastasis (TNM) classification of malignant tumors was proposed by Pierre Denoit in the mid-20th century to code the anatomic extent of tumors. Soon after, it was accepted by the Union for International Cancer Control and by the American Joint Committee on Cancer, and published in their respective staging manuals. Till 2002, the revisions of the TNM classification were based on the analyses of a database that included over 5,000 patients, and that was managed by Clifton Mountain. These patients originated from North America and almost all of them had undergone surgical treatment. To overcome these limitations, the International Association for the Study of Lung Cancer proposed the creation of an international database of lung ...

Currently, data regarding the prognosis of right-sided versus left-sided colon cancer are conflicting, however, most studies revealed a poorer survival in right-sided primary tumor location [14-18, 29].. To our knowledge this is the first population-based, propensity score adjusted analysis investigating the prognostic impact of tumor location in non-metastatic colon cancer patients. Being aware of the conflicting data and also of the challenges to handle relevant bias due to substantial imbalances regarding baseline characteristics between right- and left-sided colon cancer patients, we have intentionally selected the propensity score matching as a further statistical method in addition to common multivariate analysis to minimize confounding. In the present analysis, the cohort was partitioned into subgroups containing one or more patients with right-sided colon cancer who were matched to one or more patients with left-sided colon cancer with similar values on the observed covariates in the ...

This analysis demonstrates the promising potential of using GEP assays as predictors of poor outcomes in stage II CRC, such as cancer recurrence or death. To maximize their utility and availability, further studies will be needed to identify and validate specific gene signatures for poor prognosis i …

Author: buildbot Date: Wed Nov 14 22:10:56 2012 New Revision: 838378 Log: Staging update by buildbot for ctakes Modified: websites/staging/ctakes/trunk/content/ (props changed) websites/staging/ctakes/trunk/content/ctakes/3.0.0/user-guide-3.0.html Propchange: websites/staging/ctakes/trunk/content/ ------------------------------------------------------------------------------ --- cms:source-revision (original) +++ cms:source-revision Wed Nov 14 22:10:56 2012 @@ -1 +1 @@ -1409471 +1409472 Modified: websites/staging/ctakes/trunk/content/ctakes/3.0.0/user-guide-3.0.html ============================================================================== --- websites/staging/ctakes/trunk/content/ctakes/3.0.0/user-guide-3.0.html (original) +++ websites/staging/ctakes/trunk/content/ctakes/3.0.0/user-guide-3.0.html Wed Nov 14 22:10:56 2012 @@ -148,10 +148,9 @@ there. This example file can also be fou ,pre, Dr. Nutritious   -Medical Nutrition Therapy for Hyperlipidemia,/p, -,/li, -,/ol, -,p,Referral from: ...

Introduction Previous studies showed that TNM stages that were clinically determined before surgery were not often concordant with pathological TNM stages. However, no previous studies have examined variations of discordance of the clinical TNM stage with the pathological TNM stage among hospitals. We aimed to examine the discordance of the clinical and pathological stages among Japanese designated cancer hospitals using compiled data from the hospital-based cancer registry submitted from 286 designated cancer care hospitals in Japan.. Methods The registry data had UICC TNM stages before and after surgery for stomach, colorectal, lung and breast cancer patients treated in these hospitals. We excluded patients who received adjuvant chemotherapy or radiotherapy, patients who received care from facilities with less than 10 patients, male breast cancer and patients whose stages were unknown from the analysis. We also calculated discordance of stages that could have theoretically resulted in changes ...

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from div

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may

Watson for Oncology produced therapeutic options highly concordant with human decisions at a top-tier cancer center in China. Treatment patterns suggest that Watson for Oncology may be able to guide clinicians to minimize overtreatment of patients with high-risk stage II colon cancer with chemotherapy. Survival analyses suggest the need for further investigation to specifically assess the association between surveillance, single-agent and multiagent chemotherapy, and survival outcomes in this population. ...

TY - JOUR. T1 - Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer. T2 - The eastern cooperative oncology group results. AU - Chang, A. Y.. AU - Kim, K.. AU - Glick, J.. AU - Anderson, T.. AU - Karp, D.. AU - Johnson, D.. PY - 1993/3/3. Y1 - 1993/3/3. N2 - Background: Patients with metastatic (stage IV) non-small-cell lung cancer usually have a poor prognosis and disease refractory to chemotherapy. Three new agents-taxol, merbarone, and piroxantrone-have shown promising antitumor treatment in vitro and in animals. Taxol is an antimicrotubular agent that interferes with mitosis during cell division. Merbarone, a conjugate of thiobarbituric acid and aniline, is a topoisomerase II inhibitor, which thus inhibits DNA synthesis and tumor growth. Piroxantrone, an anthracenedione derivative, is a DNA intercalating agent that has shown potent antitumor activity in animal studies. Purpose: Our randomized phase II study was designed to evaluate the efficacy and ...

RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to chemotherapy.

Effect of pulmonary wedge resection on Ia stage non-small cell lung cancer of elderly patients, its effect on serum anti-survivin antibody, Hsp90Ã Â and CEA levels, Run-hua Ti

SOTIO presented new statistically and clinically significant results from its Phase I/II clinical trial evaluating DCVAC/LuCa, an active cellular immunotherapy product, in patients with stage IV non-small cell lung cancer. The final analysis of the data confirmed the promising clinical efficacy of DCVAC/LuCa.

Tumor staging of extrahepatic bile duct (EBD) carcinoma is problematic for a number of reasons, including definitional problems with the current T classification of the American Joint Committee on Cancer staging system and the common occurrence of severe desmoplastic stromal reaction around the adva

Conditions: Clinical Stage 0 Cutaneous Melanoma AJCC v8; Clinical Stage I Cutaneous Melanoma AJCC v8; Clinical Stage IA Cutaneous Melanoma AJCC v8; Clinical Stage IB Cutaneous Melanoma AJCC v8; Clinical Stage II Cutaneous Melanoma AJCC v8; Clinical Stage IIA Cutaneous Melanoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Colitis; Diarrhea; Malignant Genitourinary System Neoplasm; Pathologic Stage 0 Cutaneous Melanoma AJCC v8; Pathologic Stage I Cutaneous Melanoma AJCC v8; Pathologic Stage IA Cutaneous Melanoma AJCC v8; Pathologic Stage IB Cutaneous Melanoma AJCC v8; Pathologic Stage II Cutaneous Melanoma AJCC v8; Pathologic Stage IIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIC Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma ...

In rectal cancer, preoperative staging should identify early tumours suitable for treatment by surgery alone and locally advanced tumours that require therapy to induce tumour regression from the potential resection margin. Currently, local staging can be performed by digital rectal examination (DRE), endoluminal ultrasound (EUS) or magnetic resonance imaging (MRI). Each staging method was compared for clinical benefit and cost-effectiveness. The accuracy of high-resolution MRI, DRE and EUS in identifying favourable, unfavourable and locally advanced rectal carcinomas in 98 patients undergoing total mesorectal excision was compared prospectively against the resection specimen pathological as the gold standard. Agreement between each staging modality with pathology assessment of tumour favourability was calculated with the chance-corrected agreement given as the kappa statistic, based on marginal homogenised data. Differences in effectiveness of the staging modalities were compared with differences in

Although development of immune checkpoint inhibitors and various molecular target agents has extended overall survival time (OS) in advanced non-small cell lung cancer (NSCLC), a complete cure remains rare. We aimed to identify features and treatment modalities of complete remission (CR) cases in stages III and IV NSCLC by analyzing long-term survivors whose OS exceeded 3 years. From our hospital database, 1,699 patients, registered as lung cancer between 1st Mar 2004 and 30th Apr 2011, were retrospectively examined. Stage III or IV histologically or cytologically confirmed NSCLC patients with chemotherapy initiated during this period were enrolled. A Cox proportion hazards regression model was used. Data collection was closed on 13th Feb 2017. There were 164 stage III and 279 stage IV patients, including 37 (22.6%) and 51 (18.3%) long-term survivors and 12 (7.3%) and 5 (1.8%) CR patients, respectively. The long-term survivors were divided into three groups: 3 ≤ OS | 5 years, 5 years ≤ OS with tumor

Objective: Lung cancer is the leading cause of cancer-related mortality worldwide. Disease stage still remains the best prognostic factor for patients with localized non-small cell lung cancer. The TNM staging system, however, does not address the heterogeneity of this disease. Sub-classification and identification of distinct prognostic sub-groups within each stage may allow the optimization of clinical trial design and potentially improve outcome. This is a retrospective pilot study, in which we attempt to identify genomic biomarkers predictive of recurrence in stage I lung cancer by analysing copy number (CN) data obtained by next-generation sequencing. Materials and Methods: Ninety eight patients with stage I NSCLC, who underwent elective radical surgery were identified from a tissue bank of 323 tumour samples. Their demographic and surgical data, including their recurrence status were collected and an extensive database compiled. The cases were split into two cohorts depending on their ...

Despite stricter criteria and important changes for stage III melanoma criteria, the new American Joint Committee on Cancer (AJCC) 8th Edition Melanoma Staging System compares well overall to the older 7th Edition in terms of prognostic and discriminatory ability for predicting patients melanoma-specific survival, according to findings from a prospective database analysis of AJCC stage III melanoma patients (abstract 9500) presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 1-5 in Chicago.. However, there are new complexities to bear in mind, cautioned lead study coauthor Max F. Madu, MD, of the Netherlands Cancer Institute.. The 8th Edition holds up during external validation, Madu reported. There is similar prognostic accuracy in the 7th and 8th editions, and survival differentiation is comparable-though slightly worse in the 8th edition for stage IIIA vs IIIB.. The AJCC is the most widely used and validated melanoma staging system.. The ...

TY - JOUR. T1 - Are depressive symptoms associated with cancer screening and cancer stage at diagnosis among postmenopausal women? The womens health initiative observational cohort. AU - Aggarwal, Arpita. AU - Freund, Karen. AU - Sato, Alicia. AU - Adams-Campbell, Lucille L.. AU - Lopez, Ana Maria. AU - Lessin, Lawrence S.. AU - Ockene, Judith. AU - Wallace, Robert B.. AU - Williams, Carla D.. AU - Bonds, Denise E.. PY - 2008/10/1. Y1 - 2008/10/1. N2 - Background: Women with depressive symptoms may use preventive services less frequently and experience poorer health outcomes. We investigated the association of depressive symptoms with breast and colorectal cancer screening rates and stage of cancer among a cohort of postmenopausal women. Methods: In The Womens Health Initiative Observational Study, 93,676 women were followed on average for 7.6 years. Depressive symptoms were measured at baseline and at 3 years using the 6-item scale from the Center for Epidemiological Studies Depression scale ...

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.. ClinicalTrials.gov ID: NCT02201992. View Complete Trial Details & Eligibility at ClinicalTrials.gov. ...

TY - JOUR. T1 - Competing Risk of Death in Elderly Patients with Newly Diagnosed Stage I Breast Cancer. AU - Wasif, Nabil. AU - Neville, Matthew. AU - Gray, Richard. AU - Cronin, Patricia. AU - Pockaj, Barbara A. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Background: The majority of newly diagnosed breast cancers in the US are in women aged older than 65 years who can have additional comorbidities. Balancing the risks and benefits of treatment should take into account these competing risks of death. Study Design: The Surveillance, Epidemiology, and End Results Program-Medicare database was used to identify women with stage I breast cancer undergoing operations from 2004-2012. Using neural network analysis, comorbidities associated with mortality were grouped into clinically relevant categories. Cumulative incidence graphs and Fine and Gray competing risk regression analyses were used to study the association of age, race, comorbidity groupings, and tumor variables with 3 competing mortality outcomes: ...

TY - JOUR. T1 - IGFBP-3 gene methylation in primary tumor predicts recurrence of stage II colorectal cancers. AU - Fu, Tao. AU - Pappou, Emmanouil P.. AU - Guzzetta, Angela A.. AU - De Freitas Calmon, Marilia. AU - Sun, Lifeng. AU - Herrera, Alexander. AU - Li, Fan. AU - Wolfgang, Christopher L.. AU - Baylin, Stephen B.. AU - Iacobuzio-Donahue, Christine A.. AU - Tong, Weidong. AU - Ahuja, Nita. N1 - Funding Information: Supported by the National Institutes of Health (Grant Nos. CA140599 and CA127141); the Society of University Surgeons Award, Jeannik M. Littlefield-American Association of Cancer Research grant in metastatic colon cancer (Grant No. K23 CA127141); and the National Natural Science Foundation of China (Grant Nos. 81000898 and 81472289). We thank Kathy Bender and Joann Murphy for administrative support. We also thank Sharon Metzger-Gaud, Theresa Sanlorenzo-Caswell, and the Johns Hopkins Cancer Registry for assistance with the primary cancer databases.. PY - 2016. Y1 - 2016. N2 - ...

|i|Background|/i|. Evaluation of lymph node status is critical in colorectal carcinoma (CRC) treatment. However, as patients with node involvement may be incorrectly classified into earlier stages if the examined lymph node (ELN) number is too small and escape adjuvant therapy, especially for stage II CRC. The aims of this study were to assess the impact of the ELN on the survival of patients with stage II colorectal cancer and to determine the optimal number. |i|Methods|/i|. Data from the US Surveillance, Epidemiology, and End Results (SEER) database on stage II resected CRC (1988-2013) were extracted for mathematical modeling as ELN was available since 1988. Relationship between ELN count and stage migration and disease-specific survival was analyzed by using multivariable models. The series of the mean positive LNs, odds ratios (ORs), and hazard ratios (HRs) were fitted with a LOWESS (Locally Weighted Scatterplot Smoothing) smoother, and the structural break points were determined by the Chow test.

The decision to treat or not to treat a stage II colon cancer patient with adjuvant chemotherapy remains one of the most challenging areas in colorectal oncology. Currently, up to 40% of stage II patients undergo adjuvant therapy in routine clinical care (34), committing to 6 months of chemotherapy, with the associated risk of potentially serious adverse events and without a method to monitor the impact of adjuvant therapy, for an absolute risk reduction of 3 to 5%. Although multiple clinicopathological markers are now validated and can be combined to define low- and high-risk groups, only a minority of defined high-risk patients will develop recurrence. The benefit of selectively treating these patients with adjuvant therapy also remains to be conclusively proven. Diagnostic approaches that better predict the disease course in this patient population are therefore urgently required.. Here, we have taken a fundamentally different approach to address these issues. We examine postoperative blood ...

Background: Durvalumab is a category 1 recommendation per National Comprehensive Cancer Network (NCCN) guidelines for patients with unresectable Stage III non-small cell lung cancer (NSCLC) following concurrent platinum-based chemotherapy and radiation therapy (CRT). Evidence-based guidelines provide guidance to providers and can improve patient survival across several cancer types. Concordance rates with guidelines have been variable across health institutions. We aim to study the adherence and identify barriers to concordance with Durvalumab usage at our center (Plan). Methods: This is a retrospective analysis using a QI framework to develop potential process changes for guidelines concordance. All veterans with newly diagnosed stage III unresectable NSCLC seen at the Birmingham VA from October 2017 to the present were reviewed. (Do) Data including demographics, dates of diagnosis and CRT completion, Durvalumab usage and reasons for not prescribing durvalumab were collected. Results: Forty-two ...

Researchers have identified a biomarker that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy.

Activins were initially characterised as stimulators of follicle stimulating hormone production from the anterior pituitary.32 ,33 Subsequently, they were detected in reproductive and other tissues where they were found to exert important endocrine, paracrine, and autocrine actions that contribute to the regulation of cell proliferation, development, and differentiated functions.16 ,17 The multifunctional nature of activins is underscored by the finding that activin A inhibits growth in a number of cell lines, including prostate cancer cell line, vascular endothelial cells, mammary epithelial cells, and hepatocytes34-38 but stimulates the growth of BALB/c 3T3 fibroblasts, granulosa cells, erythropoietic progenitor cells, and ovarian cancer cell lines.39-42 Interestingly, inhibin α deficient mice exhibit high levels of circulating activin and develop gonadal stromal tumours,43 ,44 raising the possibility that increased activin expression may be tumorigenic under certain circumstances. This ...

Mastectomy is unnecessary in many women with stage IV breast cancer, according to a study from Indian investigators, reported at the 2013 San Antonio Breast Cancer Symposium.1. The study randomly assigned 350 patients with metastatic breast cancer to mastectomy, complete axillary dissection, plus radiation therapy, vs no locoregional treatment, and found that the nonsurgical group had no worse survival than those who underwent mastectomy.. The clinical conclusion would be that locoregional treatment of the primary tumor in women presenting with metastatic breast cancer did not result in any overall survival benefit, and hence should not be offered as a routine practice, but should be restricted as an option for palliation, according to Rajendra A. Badwe, MD, Director of the Tata Memorial Hospital, Mumbai.. All patients received anthracyclines, with or without taxanes, and were stratified by metastatic site, number of metastases, and hormone receptor status, then randomized to either ...

Background: The potential benefit of adjuvant chemotherapy in patients with Stage IA triple negative breast cancer (TNBC) has not been defined. In general, patients with T1a and T1b lesions have not been included in adjuvant chemotherapy trials and the inclusion of T1c tumors has been limited. In this study using National Cancer Data Base (NCDB) we investigated the actual use of adjuvant chemotherapy in Stage IA TNBC patients relative to tumor size (T1a, T1b, T1c) and report their survival outcomes.. Patients and Methods: Using NCDB we evaluated a cohort of 13,065 women with TNBC diagnosed between 2010-2012 who had American Joint Committee on Cancer Stage IA (node-negative with pathological T1a, T1b or T1c) tumors. Overall survival (OS) was the primary outcome variable. Based on the tumor size, patients were stratified on receipt of adjuvant chemotherapy or not. Patients were also stratified according to receipt of adjuvant radiation, radiation with boost, or none. Other adjusted variables ...

Looking for online definition of TNM staging in the Medical Dictionary? TNM staging explanation free. What is TNM staging? Meaning of TNM staging medical term. What does TNM staging mean?

Chronic obstructive pulmonary disease (COPD) is commonly staged according to the percentage of predicted forced expiratory volume in one second (FEV1%pred), but other methods have been proposed. In this study we compared seven staging methods in their performance of predicting outcomes.. We retrospectively studied 296 COPD outpatients. For each patient the disease severity was staged by separately applying the following methods: the criteria proposed by the Global Initiative for Obstructive Lung Disease (GOLD), quartiles of FEV1%pred and z score of FEV1, quartiles and specified cutoff points of the ratio of FEV1 over height squared ((FEV1·Ht−2)A and (FEV1·Ht−2)B), respectively), and quartiles of the ratio of FEV1 over height cubed (FEV1·Ht−3) and of FEV1 quotient (FEV1Q). We evaluated the performance of these methods in predicting the risks of severe acute exacerbation and the risk of all-cause mortality.. Overall, staging based on the reference-independent FEV1Q performed best in ...

Purpose: We evaluated prognostic value of the 8th edition of the American Joint Committee on Cancer/International Union for Cancer Control (AJCC/UICC) staging system for nasopharyngeal cancer and investigated whether tumor volume/metabolic information refined prognostication of anatomy based staging system. Materials and Methods: One hundred thirty-three patients with nasopharyngeal cancer who were staged with magnetic resonance imaging (MRI) and treated with intensity-modulated radiotherapy (IMRT) between 2004 and 2013 were reviewed. Multivariate analyses were performed to evaluate prognostic value of the 8th edition of the AJCC/UICC staging system and other factors including gross tumor volume and maximum standardized uptake value of primary tumor (GTV-T and SUV-T). Results: Median follow-up period was 63 months. In multivariate analysis for overall survival (OS), stage group (stage I-II vs. III-IVA) was the only significant prognostic factor. However, 5-year OS rates were not significantly ...

Qiang, G.; Xu, R.; Liu, J.; Yan, J.; Xu, Y.; Di, J.; Da, J.; Liang, C.; Shi, B.; Guo, Y.; Liu, D., 2015: The prognostic impact of preoperative PET-CT on postoperative recurrence for completely resected stage I non-small cell lung cancer

Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2. Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Govt

TAMPA, Fla. - Immunotherapy is a fast growing area of cancer research. It involves developing therapies that use a patients own immune system to fight and kill cancer. Moffitt Cancer Center is working on a new vaccine that would help early-stage breast cancer patients who have HER2 positive disease. The HER2 protein is overexpressed in nearly 25 percent of all breast cancer tumors and is associated with aggressive disease and poor prognosis. Moffitt researchers, led by physician-scientist Brian J. Czerniecki, M.D., Ph.D., have previously shown that immune cells are less able to recognize and target cancer cells that express HER2 as breast cancer progresses into a more advanced and invasive stage. This suggests that strategies that can restimulate the immune system to recognize and target HER2 early during cancer development may be effective treatment options.. The researcher team developed a vaccine that helps the immune system recognize the HER2 protein on breast cancer cells. Their approach ...

Matthias Kreppel, Nilofar-Natalie Amir Manawi, Martin Scheer, Hans-Joachim Nickenig, Daniel Rothamel, Timo Dreiseidler, Uta Drebber, Max Zinser, Joachim E. Zöller, Orlando Guntinas-Lichius, Simon Florian Preuss, Prognostic quality of the Union Internationale Contre le Cancer/American Joint Committee on Cancer TNM classification, 7th edition, for cancer of the maxillary sinus, Head & Neck, 2015, 37, 3, ...

1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. eds. Introduction and historical overview. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. eds. AJCC Cancer Staging Manual. 7th ed., 2010, Springer; p. xiii.. 2. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111 (6): 1710-1717.. 3. Sobin LH, Wittekind C eds. Lung and pleural tumours. In: Sobin LH, Wittekind C eds. UICC International Union Against Cancer, TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss, 2002; pp. 97-107.. 4. Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM staging classification: the Japanese experience. Ann Thorac Surg 2001; 71(6): 1759-1764.. 5. Ginsberg RJ. Continuing controversies in staging NSCLC: an analysis of the revised 1997 staging system. Oncology (Williston Park) 1998; 12 (1 Suppl 2): 51-54.. 6. Paci M, Sgarbi G, Ferrari G, De Franco S, Annessi ...